Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial

Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial

Abstract Background Entecavir and tenofovir disoproxil fumarate (TDF) are standard first-line treatments to prevent viral reactivation and hepatocellular carcinoma (HCC) in individuals chronically infected with the hepatitis B virus (HBV), but the long-term efficacy of the two drugs remains controve...

Full description

Bibliographic Details
Main Authors: Li-Xin Pan, Yi-Yang Wang, Zhong-Hai Li, Jia-Xi Luo, Kun-Jun Wu, Zhen-Xiu Liu, Pei-Sheng Wu, Kang Chen, Liang Ma, Xiao-Hui Fan, Jian-Hong Zhong
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Trials
Subjects:
Hepatocellular carcinoma
Hepatitis B virus
Entecavir
Tenofovir disoproxil fumarate
Online Access:https://doi.org/10.1186/s13063-023-07742-x

Internet

https://doi.org/10.1186/s13063-023-07742-x

Similar Items